$3.13
-0.01 (-0.32%)
Open$3.09
Previous Close$3.14
Day High$3.14
Day Low$3.03
52W High$11.20
52W Low$3.00
Volume—
Avg Volume11.7K
Market Cap18.10M
P/E Ratio—
EPS$-0.77
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+884.7% upside
Current
$3.13
$3.13
Target
$30.82
$30.82
$21.30
$30.82 avg
$34.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.77M | 10.40M | 9.97M |
| Net Income | -34,356,212 | 1.68M | 1.79M |
| Profit Margin | -1,940.2% | 16.1% | 17.9% |
| EBITDA | -34,210,763 | 3.32M | 3.17M |
| Free Cash Flow | — | 838.7K | 1.16M |
| Rev Growth | — | +2.0% | -1.5% |
| Debt/Equity | — | 0.33 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |